Navigation Links
Medarex to Present at the Needham Cancer Therapeutics Conference
Date:3/18/2009

PRINCETON, N.J., March 18 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the Needham & Company Cancer Therapeutics: Today & Tomorrow Conference at 11:20 a.m. Eastern Time on Thursday, March 26, 2009. The event will be webcast live and will be available in the Investor Relations section of the Medarex website at www.medarex.com. An archived edition of the presentation will be available following the event.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical trials, the subject of regulatory applications for marketing authorization or approved in Canada and Europe. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
2. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
3. Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. Medarex to Present at the RBC Capital Markets Healthcare Conference
5. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
6. Medarex Announces 2008 Third Quarter Financial Results
7. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
8. Medarex to Present at the UBS Global Life Sciences Conference
9. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
10. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
11. Medarex Announces July 10 Live Webcast of R&D Day Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... Understanding the need for better quality and ... gap that currently exists in this area, ChanTest has ... of validated ion channel and GPCR cell lines. ... ion channels control many critical physiological functions throughout the ... potential to treat a variety of human diseases. ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Robert Harman, DVM, ... Medicine company, is proud to announce the relaunch of his ... with a new series called “ What are Stem Cells ... an honest and straightforward foundation in the basics of stem ... decision on the right type of treatment when considering regenerative ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
... , , CHICAGO, Sept. 17 ... risk management services, insurance and ... issued the findings of its 2009 Clinical Trials Risk Map ... pharmaceutical and medical device companies conduct business ...
... STAMFORD, Conn., Sept. 17 Cowen Healthcare ... established a Strategic Advisory Board to extend the Firm,s ... The Board will be comprised of industry veterans with ... is expected to supplement Cowen Royalty,s due diligence, opportunity ...
... ... pharma, biotech, medical device, and software industries, among others , ... Boston, Massachusetts (Vocus) -- Brown Rudnick, an ... Godward Kronish LLP has joined the Firm,s Boston office. With over 35 years of ...
Cached Biology Technology:Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map 2Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map 3Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map 4Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map 5Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 2Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 3Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 4Veteran Intellectual Property Team Joins Brown Rudnick 2
(Date:7/11/2014)... relationships with other group members to reduce aggression and ... the strategy for grooming activities shows a certain pattern ... the scientific journal Biology Letters . , Grooming ... practiced without ulterior motives. To be groomed has hygienic ... grooming another individual can provide access to infants, mating ...
(Date:7/11/2014)... The increased risk of kidney injury related to the ... the mass of HES molecules, according to a report ... the International Anesthesia Research Society (IARS). , The "total ... HES on cultured human renal proximal tubule cells (PTCs), ... colleagues of University Hospital Wrzburg, Austria. Other factorssuch ...
(Date:7/11/2014)... Evidence exists that cannabinoid receptor type 1 ... Ca2+ influx, and reduce neurotransmitter release. However, ... 1 can increase extracellular Ca2+ influx and ... his team, Tongji Hospital Affiliated to Tongji ... Technology, China used whole cell voltage-clamp and ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... the popular Newscripts page in Chemical & Engineering News ... romance and hauled in a catch that includes fake Viagra ... the bedbug. C&EN is the weekly newsmagazine of the American ... first on a study that checked the authenticity of Viagra ...
... Kansas State University professor,s research on breast cancer stem ... recurrence and metastasis -- the major causes of death ... of biochemistry and molecular biophysics, has received a four-year ... at the National Institutes of Health -- to study ...
... SAN FRANCISCO February 12, 2013 New findings from ... may predict whether a person is likely to develop age-related ... more than nine million Americans, these genes do not predict ... medications most widely used to treat the "wet" form of ...
Cached Biology News:Research improving breast cancer treatment by targeting tumor initiating cells 2Research improving breast cancer treatment by targeting tumor initiating cells 3Major clinical trial finds no link between genetic risk factors and 2 top wet AMD treatments 2
... Andrew J. Davison and ... • Contents include: information ... viruses, paramyxoviruses, influenza and ... covers analysis of viral ...
... U. Desselberger (1995) • This book ... together classical and molecular techniques currently ... infections and analysis of virus-specific antibodies ... are presented covering immunoassays, blotting and ...
...
... provide rapid and efficient removal of short ... salts from PCR products (Figure 1). The ... Binding Buffer options for fragments >100 bp ... in either single column or 96-well plate ...
Biology Products: